{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:08:56Z","timestamp":1790125736870,"version":"4.0.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-024-01841-z","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T14:25:49Z","timestamp":1724423149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Situational prevention in migraine: are we doing the right thing?"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-5039","authenticated-orcid":false,"given":"Lanfranco","family":"Pellesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-4128","authenticated-orcid":false,"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"issue":"7","key":"1841_CR1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/head.14775","volume":"64","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, Ailani J, Mullin K, Pavlovic JM, Tepper SJ, Dodick DW et al (2024) Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacks. Headache 64(7):859\u2013864. https:\/\/doi.org\/10.1111\/head.14775","journal-title":"Headache"},{"issue":"1","key":"1841_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s10194-023-01625-x","volume":"24","author":"H Zhang","year":"2023","unstructured":"Zhang H, Qi JZ, Zhang ZH (2023) Comparative efficacy of different treatments for menstrual migraine: a systematic review and network meta-analysis. J Headache Pain 24(1):81. https:\/\/doi.org\/10.1186\/s10194-023-01625-x","journal-title":"J Headache Pain"},{"key":"1841_CR3","doi-asserted-by":"publisher","unstructured":"Gosalia H, Moreno-Ajona D, Goadsby PJ (2024) Medication-overuse headache: a narrative review. J Headache Pain 2024;25(1):89. https:\/\/doi.org\/10.1186\/s10194-024-01755-w","DOI":"10.1186\/s10194-024-01755-w"},{"key":"1841_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2147\/DHPS.S304373","volume":"13","author":"F Lo Castro","year":"2021","unstructured":"Lo Castro F, Guerzoni S, Pellesi L (2021) Safety and risk of medication overuse headache in lasmiditan and second- generation gepants: a rapid review. Drug Healthc Patient Saf 13:233\u2013240. https:\/\/doi.org\/10.2147\/DHPS.S304373","journal-title":"Drug Healthc Patient Saf"},{"issue":"4","key":"1841_CR5","doi-asserted-by":"publisher","first-page":"333102424123294","DOI":"10.1177\/03331024241232944","volume":"44","author":"R Croop","year":"2024","unstructured":"Croop R, Berman G, Kudrow D, Mullin K, Thiry A, Lovegren M et al (2024) A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia 44(4):3331024241232944. https:\/\/doi.org\/10.1177\/03331024241232944","journal-title":"Cephalalgia"},{"key":"1841_CR6","doi-asserted-by":"publisher","unstructured":"Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J et al (2021) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 2021;22(1):128. https:\/\/doi.org\/10.1186\/s10194-021-01335-2","DOI":"10.1186\/s10194-021-01335-2"},{"issue":"4","key":"1841_CR7","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/ana.25831","volume":"88","author":"IA Mulder","year":"2020","unstructured":"Mulder IA, Li M, de Vries T, Qin T, Yanagisawa T, Sugimoto K et al (2020) Anti-migraine calcitonin gene-related peptide receptor antagonists worsen cerebral ischemic outcome in mice. Ann Neurol 88(4):771\u2013784. https:\/\/doi.org\/10.1002\/ana.25831","journal-title":"Ann Neurol"},{"issue":"17","key":"1841_CR8","doi-asserted-by":"publisher","first-page":"e1897","DOI":"10.1212\/WNL.0000000000201008","volume":"99","author":"S de Vries Lentsch","year":"2022","unstructured":"de Vries Lentsch S, van der Arend BWH, van den Brink AM, Terwindt GM (2022) Blood pressure in migraine patients treated with monoclonal anti-CGRP (receptor) antibodies: a prospective follow-up study. Neurology 99(17):e1897\u2013e1904. https:\/\/doi.org\/10.1212\/WNL.0000000000201008","journal-title":"Neurology"},{"issue":"3","key":"1841_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/head.14679","volume":"64","author":"N Chhabra","year":"2024","unstructured":"Chhabra N, Mead-Harvey C, Dodoo CA, Iser C, Taylor H, Chaudhary H et al (2024) Blood pressure elevation in erenumab-treated patients with migraine: a retrospective real-world experience. Headache 64(3):233\u2013242. https:\/\/doi.org\/10.1111\/head.14679","journal-title":"Headache"},{"issue":"8","key":"1841_CR10","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/cpdd.1244","volume":"12","author":"R Bhardwaj","year":"2023","unstructured":"Bhardwaj R, Ivans A, Stringfellow J, Morris B, Coric V, Croop R et al (2023) Rimegepant 75\u00a0mg in subjects with hepatic impairment: results of a phase 1, Open-Label, Single-Dose, parallel-group study. Clin Pharmacol Drug Dev 12(8):790\u2013800. https:\/\/doi.org\/10.1002\/cpdd.1244","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"1841_CR11","doi-asserted-by":"publisher","first-page":"333102423117913","DOI":"10.1177\/03331024231179131","volume":"43","author":"R Bertz","year":"2023","unstructured":"Bertz R, Bhardwaj R, Morris BA, Ashbrenner E, Coric V, Croop R (2023) A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants. Cephalalgia 43(6):3331024231179131. https:\/\/doi.org\/10.1177\/03331024231179131","journal-title":"Cephalalgia"},{"issue":"10268","key":"1841_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM et al (2021) Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet 397(10268):51\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)32544-7","journal-title":"Lancet"},{"key":"1841_CR13","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s42399-020-00390-1","volume":"2","author":"A Singh","year":"2020","unstructured":"Singh A, Gupta D, Sahoo AK (2020) Acute migraine: can the new drugs clinically outpace? SN Compr Clin Med 2:1132\u20131138. https:\/\/doi.org\/10.1007\/s42399-020-00390-1","journal-title":"SN Compr Clin Med"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01841-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01841-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01841-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T14:25:52Z","timestamp":1724423152000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01841-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1841"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01841-z","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Lanfranco Pellesi serves as member of Editorial Board of European Journal of Medical Research and Junior Editorial Board of The Journal of Headache and Pain. Paolo Martelletti serves as Editor in Chief of The Journal of Headache and Pain, Editor in Chief of SN Comprehensive Clinical Medicine, Member of Editorial Board of Internal and Emergency Medicine, Pain & Therapy, Expert Review of Neurotherapeutics, Neurology & Therapy, and Expert Member of European Medicines Agency.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}